Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 20/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | JAK1 | P23458 | 1/20 | 1.00 |
| ▸ | TTK | P33981 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | TXK | P42681 | 1/20 | 1.00 |
| ▸ | BLK | P51451 | 1/20 | 1.00 |
| ▸ | BTK | Q06187 | 1/20 | 1.00 |
| ▸ | ITK | Q08881 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17202389 | 1.00 | JAK3 (1.00) | JAK3JAK2EGFRJAK1TTK | |
| SCHEMBL30925312 | 1.00 | JAK3 (1.00) | JAK3JAK2EGFRJAK1TTK | |
| SCHEMBL17209829 | 0.94 | JAK3 (1.00) | JAK3JAK2EGFRJAK1TTK | |
| SCHEMBL17209789 | 0.93 | JAK3 (1.00) | JAK3JAK2EGFRJAK1TTK | |
| SCHEMBL17209883 | 0.92 | JAK3 (1.00) | JAK3JAK2EGFRJAK1TTK | |
| SCHEMBL17209823 | 0.92 | JAK3 (1.00) | JAK3JAK2EGFRJAK1TTK | |
| SCHEMBL17209776 | 0.92 | JAK3 (1.00) | JAK3JAK2EGFRJAK1TTK | |
| SCHEMBL17209790 | 0.92 | JAK3 (1.00) | JAK3JAK2EGFRJAK1TTK | |
| SCHEMBL17209896 | 0.91 | JAK3 (1.00) | JAK3JAK2EGFRJAK1TTK | |
| SCHEMBL17209797 | 0.91 | JAK3 (0.86) | JAK3JAK2EGFRJAK1TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-4629993-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | Kartos Therapeutics (US) | 2025-10-15 | — | — | EP | claimed |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | KARTOS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | claimed |
| WO-2024124240-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS (US) | 2024-06-13 | — | — | WO | claimed |
| US-20230158032-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | Universitätsklinikum Jena (DE) | 2023-05-25 | — | — | US | claimed |
| EP-4121171-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | Universitätsklinikum Jena (DE) | 2023-01-25 | — | — | EP | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4629993-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | Kartos Therapeutics (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-4590700-A1 | TREATING SKIN IRRITATION FROM APPLICATION OF AN ALTERNATING ELECTRIC FIELD | Novocure GmbH (CH) | 2025-07-30 | — | — | EP | disclosed |
| US-12324817-B2 | Method of inducing dedifferentiation of somatic cells with small molecules to prepare rejuvenated mesenchymal stem cells and uses thereof | Shenzhen Alpha Biopharmaceutical Co. Ltd. (CN) | 2025-06-10 | — | — | US | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | KARTOS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-11938143-B2 | Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers | AKIRABIO, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230310437-A1 | TTP PHOSPHORYLATION FOR THE IDENTIFICATION OF PERSONALIZED MEDICINES | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-10-05 | — | — | US | disclosed |
| WO-2023107878-A1 | COMPOSITIONS AND METHODS OF SENECA VALLEY VIRUS (SVV) RELATED CANCER THERAPY | ONCORUS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230158032-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | Universitätsklinikum Jena (DE) | 2023-05-25 | — | — | US | disclosed |
| US-11648251-B2 | TTP phosphorylation as a biomarker in targeted therapy | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-05-16 | — | — | US | disclosed |
| US-20230122664-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | CUSTOMERS BANK | 2023-04-20 | — | — | US | disclosed |
| EP-4121171-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | Universitätsklinikum Jena (DE) | 2023-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | JAK2, JAK1, MPL | JAK3 21/4885JAK2 1/4885EGFR 499/4885 |
| US-20230122664-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | TYMP, HBZ, HBB | JAK3 1376/4885JAK2 774/4885EGFR 3896/4885 |
| US-11938143-B2 | Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers | TYMP, HBZ, CDA | JAK3 1435/4885JAK2 779/4885EGFR 3886/4885 |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | JAK2, JAK1, PDPK1 | JAK3 19/4885JAK2 1/4885EGFR 989/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | JAK3 91/4885JAK2 1/4885EGFR 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.